In this study, we demonstrated that the combination of MK-5108 and trametinib shows a synergistic antitumor effect in RAS/RAF mutant colon cancer and that the combination therapy may be more effective in wt TP53 cells. The gene discussed is TP53; the disease is colonic neoplasm.